-

Closed Loop Medicine Appoints Kate Woolland as Chief Operating Officer

Key executive appointment supports strategic operational delivery of the Company’s product and partnership programs

LONDON--(BUSINESS WIRE)--Closed Loop Medicine Ltd., a leading TechBio company developing combination prescription drug plus software therapy products that enable personalized dose optimization, today announced that it has appointed Kate Woolland as Chief Operating Officer. Kate joins CEO, Dr. Hakim Yadi PhD OBE, on the executive team to guide organizational and operational delivery of the Company’s lead programs, products and commercial partnerships.

Kate’s appointment follows Closed Loop Medicine’s recent announcement of a co-development partnership deal with Pharmanovia, a global lifecycle management healthcare company, for drug plus software product solutions for the treatment of hypertension(1). Bringing extensive strategic business experience, including over 13 years in healthcare, Kate strengthens the executive team and supports the Company as it continues to scale commercial development. As COO, she will play a pivotal role in leading collaboration across the multi-disciplinary team whilst working closely with current and future commercial partners to drive delivery of Closed Loop Medicine’s products to market.

In her previous role, Kate was Chief Delivery Officer at ieso Digital Health, where she led product, design, clinical trial operations, commercial, regulatory and program management functions. During that time, Kate secured ieso’s first commercial partnerships and launched its first medical device; demonstrating capability that helped secure $53m Series B investment. Prior to this, Kate was a Partner for PA Consulting, during which time she supported the development of numerous commercial partnerships and built a healthcare system transformation consulting business worth over £10m p.a. She holds a Masters in Mathematics from The University of Manchester.

Kate Woolland, COO of Closed Loop Medicine, added: I am thrilled to join the Closed Loop Medicine team at such an exciting stage. Leveraging the capabilities of our incredible technologies to revolutionize the dosing of medicines has the potential to help patients and healthcare professionals better manage health conditions, improve quality of life and health outcomes for millions of people. I am delighted to have the opportunity to play a part in such ground-breaking work.”

Dr. Hakim Yadi PhD OBE, CEO & Co-Founder of Closed Loop Medicine, commented: “As Chief Operating Officer, Kate brings a wealth of experience in optimizing and improving health systems and helping scale next generation digitally delivered health services from her time at ieso. We are on a mission to provide the right dose of medicine to patients and are excited to have Kate join us on this journey, helping build and develop our team dedicated to dose optimization and combination products.”

1. Press release (17th May 2023): https://www.closedloopmedicine.com/closed-loop-medicine-and-pharmanovia-enter-a-global-co-development-partnership-for-precision-medicine-combination-therapeutics/

For more information visit: www.closedloopmedicine.com

Contacts

Zyme Communications
Dr. Maria Spyrou
Email: maria.spyrou@zymecommunications.com

Closed Loop Medicine


Release Versions

Contacts

Zyme Communications
Dr. Maria Spyrou
Email: maria.spyrou@zymecommunications.com

Social Media Profiles
More News From Closed Loop Medicine

Closed Loop Medicine Launches First Personalized GLP-1 Dosing Platform in U.S.

LONDON--(BUSINESS WIRE)--Closed Loop Medicine Ltd (CLM), a leader in personalized pharmaceutical dosing, today announced the U.S. launch of WeDosify, which enables clinicians to personalize GLP-1 titration at scale. The launch comes as the global anti-obesity market, valued at over $30 billion in 2024, is projected to reach $100 billion by 2030. Despite this growth, GLP-1 therapies face a major real-world challenge: up to 44% of patients discontinue treatment within six months, with that figure...

US Patent Office Grants Closed Loop Medicine Key Patents for Cardiometabolic Capabilities in GLP-1 and Direct Oral Anti-Coagulants (DOAC) Therapies

LONDON--(BUSINESS WIRE)--Closed Loop Medicine Ltd., a leader in AI-enabled precision medicines, today announced the expansion of its US patent portfolio. Strengthening its cardiometabolic treatment portfolio, the Company now has patents covering advancements in GLP-1 therapies for obesity and diabetes, and direct oral anticoagulants (DOACs) for cardiovascular health. Closed Loop Medicine holds over 65 filings across 16 patent families, marking a significant milestone in its mission to deliver p...

Closed Loop Medicine Appoints Luba Greenwood as Chair of the Board of Directors

LONDON--(BUSINESS WIRE)--Closed Loop Medicine Ltd., a leading TechBio company leveraging AI, machine learning, and personalized dosing to enhance drug development, today announced the appointment of Luba Greenwood as Chair of its Board of Directors. Luba is a distinguished executive and investor with over 20 years’ experience in healthcare and tech. She has led over $10 billion USD in deals and investment over multiple therapeutic areas, leading success and scaling companies across the life sci...
Back to Newsroom